GlassScriptPhysician profile
Andy Joseph Thanjan
NPI 1306083696
$11,138.15
in general payments reported to CMS, 2019-2025
42 companies · $1,950 in 2025
The $1,950 reported for 2025 was more than what 78% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,454 · 2020: $643 · 2021: $1,360 · 2022: $2,073 · 2023: $1,561 · 2024: $2,097 · 2025: $1,950.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,577 · Education: $31.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,577.10 |
| Education | $31.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,671.78 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $1,331.13 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,233.57 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $927.73 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $422.70 | 2021-2023 | Zeposia |
| Genzyme Corporation | $409.59 | 2022-2025 | |
| Qol Medical, LLC | $329.11 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $238.58 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $217.75 | 2024-2025 | Voquezna |
| Pfizer INC. | $204.86 | 2020-2025 | |
| Gilead Sciences, INC. | $182.02 | 2019-2022 | |
| Allergan, INC. | $178.97 | 2019-2020 | |
| Medtronic, INC. | $145.04 | 2022 | |
| Merck Sharp & Dohme LLC | $137.16 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $128.86 | 2020-2023 | Linzess |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $118.58 | 2019-2024 | Rebyota |
| Madrigal Pharmaceuticals | $112.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $107.75 | 2024-2025 | Iqirvo, Bylvay |
| Organon LLC | $99.33 | 2022-2024 | Hadlima |
| Nestle Healthcare Nutrition INC. | $88.34 | 2021-2022 | |
| Daiichi Sankyo INC. | $76.28 | 2019-2024 | Injectafer |
| Boston Scientific Corporation | $69.85 | 2022-2025 | Spyglass |
| Braintree Laboratories, INC. | $66.63 | 2022-2025 | Suflave, Sutab |
| Intra-Sana Laboratories | $61.61 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Lilly USA, LLC | $59.71 | 2023-2025 | Omvoh |
| Celltrion USA INC. | $55.94 | 2024-2025 | Zymfentra, Vegzelma |
| Alnylam Pharmaceuticals INC. | $53.29 | 2022 | |
| Biocon Biologics INC | $48.88 | 2024-2025 | Hulio |
| Apollo Endosurgery US INC | $37.87 | 2022-2023 | Overstitch Endoscopic Suturing System |
| Fresenius Kabi USA, LLC | $36.22 | 2023-2024 | Idacio |
| Aimmune Therapeutics, INC. | $35.36 | 2025 | Vowst |
| Mallinckrodt Hospital Products INC. | $35.25 | 2025 | Terlivaz |
| Vivus LLC | $31.05 | 2024-2025 | Qsymia, Pancreaze |
| Sandoz INC. | $30.32 | 2023 | |
| Alcresta Therapeutics, INC. | $26.67 | 2025 | Relizorb |
| Echosens North America, INC. | $24.94 | 2024 | Fibroscan |
| Intercept Pharmaceuticals, INC. | $22.14 | 2023 | Ocaliva |
| Covidien LP | $19.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.98 | 2022 | |
| W. L. Gore & Associates, INC. | $14.77 | 2022 | |
| Olympus America INC. | $14.48 | 2021 | |
| Romark Laboratories, Lc | $13.55 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Thanjan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.